Author: Solinas, Cinzia; Perra, Laura; Aiello, Marco; Migliori, Edoardo; Petrosillo, Nicola
Title: A critical evaluation of glucocorticoids in the treatment of severe COVID-19 Cord-id: m2b836k8 Document date: 2020_6_24
ID: m2b836k8
Snippet: The viral infection by SARS-CoV-2, has revolutionized the life of the majority of human beings, challenging national health systems worldwide, and pushing researchers to rapidly find adequate preventive and treatment strategies. No therapies have been shown effective, with the exception of dexamethasone, a glucocorticoid that was recently proved to be the first life-saving drug in this disease. Remarkably, around 20% of infected people develop a severe form of COVID-19, giving rise to respirator
Document: The viral infection by SARS-CoV-2, has revolutionized the life of the majority of human beings, challenging national health systems worldwide, and pushing researchers to rapidly find adequate preventive and treatment strategies. No therapies have been shown effective, with the exception of dexamethasone, a glucocorticoid that was recently proved to be the first life-saving drug in this disease. Remarkably, around 20% of infected people develop a severe form of COVID-19, giving rise to respiratory and multi-organ failures requiring subintensive and intensive care interventions. This phenomenon is due to an excessive immune response that damages pulmonary alveoli, leading to a cytokine and chemokine storm with systemic effects. Indeed glucocorticoids’ role in regulating this immune response is controversial, and they have been used in clinical practice in a variety of countries, even without a previous clear consensus on their evidence-based benefit.
Search related documents:
Co phrase search for related documents- action genomic mechanism and acute respiratory sars syndrome coronavirus: 1
- activity influence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- activity influence and acute respiratory distress syndrome: 1, 2
- activity influence and acute respiratory sars syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
- activity influence and lmwh molecular weight heparin: 1
- activity influence and low lmwh molecular weight heparin: 1
- activity influence and lung systemic: 1
- activity number and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activity number and acute respiratory distress syndrome: 1, 2, 3, 4
- activity number and acute respiratory sars syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory and lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory and low dose dexamethasone: 1, 2, 3, 4, 5, 6, 7
- acute respiratory and low lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory and lung systemic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and lung systemic inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory distress syndrome and lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory distress syndrome and low dose dexamethasone: 1, 2, 3
- acute respiratory distress syndrome and low lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory distress syndrome and lung systemic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date